118 related articles for article (PubMed ID: 10321723)
1. Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.
Yoon JM; Han SH; Kown OB; Kim SH; Park MH; Kim BK
Life Sci; 1999; 64(16):1435-45. PubMed ID: 10321723
[TBL] [Abstract][Full Text] [Related]
2. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
3. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
4. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
5. Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas.
Psarras K; Ueda M; Yamamura T; Ozawa S; Kitajima M; Aiso S; Komatsu S; Seno M
Protein Eng; 1998 Dec; 11(12):1285-92. PubMed ID: 9930679
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein.
Chandler LA; Sosnowski BA; McDonald JR; Price JE; Aukerman SL; Baird A; Pierce GF; Houston LL
Int J Cancer; 1998 Sep; 78(1):106-11. PubMed ID: 9724101
[TBL] [Abstract][Full Text] [Related]
7. An EGF-pseudomonas exotoxin A recombinant protein with a deletion in toxin binding domain specifically kills EGF receptor bearing cells.
Lee CH; Lee EC; Tsai ST; Kung HJ; Liu YC; Hwang J
Protein Eng; 1993 Jun; 6(4):433-40. PubMed ID: 8332601
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
Jinno H; Ueda M; Ozawa S; Kikuchi K; Ikeda T; Enomoto K; Kitajima M
Cancer Chemother Pharmacol; 1996; 38(4):303-8. PubMed ID: 8674151
[TBL] [Abstract][Full Text] [Related]
9. Humanization of immunotoxins.
Rybak SM; Hoogenboom HR; Meade HM; Raus JC; Schwartz D; Youle RJ
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3165-9. PubMed ID: 1565609
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells.
Hoshimoto S; Ueda M; Jinno H; Kitajima M; Futami J; Seno M
Anticancer Res; 2006; 26(2A):857-63. PubMed ID: 16619480
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of ribonucleolytic toxin restrictocin-based chimeric toxins targeted to epidermal growth factor receptor.
Rathore D; Batra JK
FEBS Lett; 1997 May; 407(3):275-9. PubMed ID: 9175867
[TBL] [Abstract][Full Text] [Related]
12. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis.
Harper JW; Vallee BL
Biochemistry; 1989 Feb; 28(4):1875-84. PubMed ID: 2719939
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin.
Kawase Y; Ohdate Y; Shimojo T; Taguchi Y; Kimizuka F; Kato I
FEBS Lett; 1992 Feb; 298(2-3):126-8. PubMed ID: 1544433
[TBL] [Abstract][Full Text] [Related]
14. Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: efficacy in an animal model of experimental colitis.
Hall FL; Kaiser A; Liu L; Chen ZH; Hu J; Nimni ME; Beart RW; Gordon EM
Int J Mol Med; 2000 Dec; 6(6):635-43. PubMed ID: 11078822
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy.
Sun R; Zhu Y; Feng H; Yang Z; Bian X; Gu P; Wang C; Liu Y
Cell Physiol Biochem; 2015; 35(5):1877-91. PubMed ID: 25871436
[TBL] [Abstract][Full Text] [Related]
16. Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent.
Kim DG; Kim EY; Kim YR; Kong IS
J Microbiol Biotechnol; 2015 Jan; 25(1):119-26. PubMed ID: 25152055
[TBL] [Abstract][Full Text] [Related]
17. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.
Moriai T; Kobrin MS; Hope C; Speck L; Korc M
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10217-21. PubMed ID: 7937865
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase 1.
Jinno H; Ueda M; Ozawa S; Ikeda T; Enomoto K; Psarras K; Kitajima M; Yamada H; Seno M
Life Sci; 1996; 58(21):1901-8. PubMed ID: 8637416
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.
Shaw JP; Akiyoshi DE; Arrigo DA; Rhoad AE; Sullivan B; Thomas J; Genbauffe FS; Bacha P; Nichols JC
J Biol Chem; 1991 Nov; 266(31):21118-24. PubMed ID: 1939154
[TBL] [Abstract][Full Text] [Related]
20. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
